1. Leggett EJ. Aminoglycosides In: Bennet JE, Dolin R, Blaser MJ (eds). Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases, Philadelphia, 9. Ed., Elsevier, 2019:305-317.
2. Özdemir D, Willke-Topçu A. Aminoglikozitler. Editörler: Willke-Topçu A, Söyletir G, Doğanay M. Enfeksiyon Hastalıkları ve Mikrobiyolojisi, 4. Baskı. Nobel Tıp Kitabevleri, 2017:283-290.
3. Türkiye İlaç ve Tıbbi Cihaz Kurumu. T.C. Sağlık Bakanlığı. SKRS E-reçete ilaç ve diğer farmasötik ürünler listesi. Erişim tarihi: 2 Haziran 2024. İnternet adresi: https://www.titck.gov.tr/dina-
mikmodul/43
4. Tompkins K, van Duin D. Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions. Eur J Clin Microbiol Infect Dis 2021;40(10):2053-2068. doi:
10.1007/s10096-021-04296-1. Epub 2021 Jun 24. PMID: 34169446; PMCID: PMC8527571.
5. Fu J, Wu Z, Zhang L. Clinical applications of the naturally occurring or synthetic glycosylated low molecular weight drugs. Prog Mol Biol Transl Sci. 2019;163:487-522. doi: 10.1016/bs.pm-
bts.2019.03.005. Epub 2019 Mar 25. PMID: 31030760.
6. Dezanet C, Kempf J, Mingeot-Leclercq MP, Décout JL. Amphiphilic Aminoglycosides as Medicinal Agents. Int J Mol Sci 2020;21(19):7411.
7. Desai NR, Shah SM, Cohen J, McLaughlin M, Dalal H. Zosyn (piperacillin/ tazobactam) reformulation: expanded compatibility and co-administration with lactated Ringer’s solutions and
selected aminoglycosides. Ther Clin Risk Man 2008;4:303–314.
8. Block M, Blanchard DL. Aminoglycosides. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541105/
9. Jadhav RW, Kobaisi MA, Jones LA, Vinu A, Bhosale SV. The Supramolecular Self-Assembly of Aminoglycoside Antibiotics and their Applications. ChemistryOpen 2019;8(9):1154-1166.
10. Thy M, Timsit J-F, de Montmollin E. Aminoglycosides for the Treatment of Severe Infection Due to Resistant Gram-Negative Pathogens. Antibiotics 2023;12(5):860.
11. Gandhi K, Dhiman S, Arora R, et al. Exploring Antibiotic-Potentiating Effects of Tobramycin–Deferiprone Conjugates in Pseudomonas aeruginosa. Antibiotics 2023; 12(8):1261.
12. Maurin M, Raoult D. Use of aminoglycosides in treatment of infections due to intracellular bacteria. Antimicrob Agents Chemother 2001;45:2977–2986.
13. Spengler G, Kincses A, Gajdács M, Amaral L. New Roads Leading to Old Destinations: Efflux Pumps as Targets to Reverse Multidrug Resistance in Bacteria. Molecules 2017; 22(3):468.
14. Doi Y, Wachina J, Arakawa Y. Aminoglycoside resistance. The emergence of acquired 16S ribosomal RNA methyltransferases. Infect Dis Clin N Am 2016;30:523–537.
15. Ramirez MS, Tolmasky ME. Amikacin: Uses, Resistance, and Prospects for Inhibition. Molecules 2017;22(12):2267.
16. Khan A, Miller WR, Axell-House D, Munita JM, Arias CA. Antimicrobial Susceptibility Testing for Enterococci. J Clin Microbiol 2022;60(9):e0084321.
17. Goodlet KJ, Benhalima FZ, Nailor MD. A Systematic Review of Single-Dose Aminoglycoside Therapy for Urinary Tract Infection: Is It Time To Resurrect an Old Strategy? Antimicrob Agents
Chemother 2018;63(1):e02165-18.
18. Craig WA. Optimizing aminoglycoside use. Crit Care Clin 2011;27:107–121.
19. Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and Critically Ill Patient
Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and
Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monito-
ring in critically ill adult patients: a Position Paper. Intensive Care Med 2020;46(6):1127-1153.
20. Nagai J, Takano M. Entry of aminoglycosides into renal tubular epithelial cells via endocytosis-dependent and endocytosis-independent pathways. Biochem Pharmacol 2014;90(4):331-7.
21. Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, McDonald WJ. High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis 1992;165:1026–
1032.
22. Bitner-Glindzicz M, Pembrey M, Duncan A, et al. Prevalence of mitochondrial 1555 A-to-G mutation in European children. N Engl J Med 2009;360:640–642.
23. Janky K, Steyger PS. Mechanisms and Impact of Aminoglycoside-Induced Vestibular Deficits. Am J Audiol 2023;32(3S):746-760.
24. Drew RH. Aminoglycosides. UpToDate. 2024. Available from: https://www.uptodate.com/contents/aminoglycosides#H30
25. Bowers DR, Liew YX, Lye DC, Kwa LA, Hsu L, Tam VH. Outcome of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents
Chemother. 2013;57:1270–1274.
26. Stoneham SM, Cantillon DM, Waddell SJ, Llewelyn MJ. Spontaneously Occurring Small-Colony Variants of Staphylococcus aureus Show Enhanced Clearance by THP-1 Macrophages. Front
Microbiol 2020;11:1300.